A recent study published in the Journal of Molecular Sciences illustrates how Exo–101 modulates cells and their microenvironment, to reduce inflammation and promote homeostasis. These results support the development of Exo–101 as an adjuvant therapy for inflammatory skin diseases, such as psoriasis.
Psoriasis is an inflammatory skin disease, that appears as patches of red, dry, and scaly skin. Characteristically, antimicrobial peptides S100A7 and DEFB4, as well as pro–inflammatory mediators IL6, IL8, CXCL10, and COX2 are all found to be upregulated in psoriasis patients. We were able to show Exo–101’s effect in modulating the production of the above–mentioned markers, with a particularly strong impact on antimicrobial peptides, by using a 3D model of psoriatic skin. In vivo, Exo–101 did not significantly affect overall disease burden in a model of imiquimod–induced psoriasis, but markedly reduced epidermal thickness, that is typically seen in these patients.
Overall, this publication details the immunomodulatory effects of Exo–101, which could prove beneficial to patients suffering from inflammatory skin diseases, by modulating macrophage and T–cell responses.
Click here to read this and other publications by our team.